Sentence: We designed a phase I trial to determine the maximum-tolerated dose ( MTD ) and pharmacodynamic effects of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer refractory to standard therapies .
Drug combination annotation:
[{'class': 'POS', 'spans': ['Cixutumumab', 'temsirolimus'], 'is_context_needed': True}]